@article{cb8dbd58762f44408193d1c19cdf1999,
title = "Scientific Advances and New Frontiers in Mesothelioma Therapeutics",
abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.",
keywords = "Biomarkers, Chemotherapy, Immunotherapy, Malignant pleural mesothelioma, Oncology therapeutics",
author = "Luciano Mutti and Tobias Peikert and Robinson, {Bruce W.S.} and Arnaud Scherpereel and Tsao, {Anne S.} and {de Perrot}, Marc and Woodard, {Gavitt A.} and Jablons, {David M.} and Jacinta Wiens and Hirsch, {Fred R.} and Haining Yang and Michele Carbone and Anish Thomas and Raffit Hassan",
note = "Funding Information: Disclosure: Dr. Scherpereel reports personal fees from BMS, MSD, Boehringer Ingelheim, AstraZeneca, and Roche for service on advisory boards, as well as fees to his institution from BMS, MSD, Boehringer Ingelheim, AstraZeneca, Lilly, Epizyme, Bayer, and Roche for serving as principal investigator or coprincipal investigatory on clinical trials outside the submitted work. Dr. Tsao reports grants from the National Institutes of Health/National Cancer Institute, Genentech, the American Cancer Society, Boehringer Ingelheim, Medimmune, Millennium, Polaris Pharmaceuticals, Seattle Genetics, Verastem, the Department of Defense, and GlaxoSmith Kline Pharmaceuticals; personal fees from Clinical Care Options for speakers bureau participation; and personal fees from Genentech and Merck for serving on advisory boards outside the submitted work. Dr. de Perrot reports personal fees from Bayer and Merck outside the submitted work. Dr. Hirsch is coinventor of a University of Colorado–owned patent titled “EGFR Immunohistochemistry and Fluorescence In Situ Hybridization as Predictive Biomarkers for EGFR Therapy.” Dr. Hirsch has participated in advisory boards for BMS, Genentech/Roche, HTG, Lilly, Merck, Pfizer, and Ventana, and Dr. Hirsch{\textquoteright}s laboratory has received research grants (through the University of Colorado) from Genentech, BMS, Lilly, Bayer, and Clovis. Dr. Carbone reports grants from National Institutes of Health/National Cancer Institute, the Department of Defense, V Foundation for Cancer Research, University of Hawaii Foundation (Pathogenesis of Malignant Mesothelioma) through donations from Honeywell International, Inc., and Riviera United-4-a Cure (which had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript) during the conduct of the study. Dr. Carbone has pending patent applications on BAP1, a patent titled “Using Anti-HMGB1 Monoclonal Antibody or Other HMGB1 Antibodies as a Novel Mesothelioma Therapeutic Strategy” (Patent No. 9,561,274 issued), and a patent titled “HMGB1 as a Biomarker for Asbestos Exposure and Mesothelioma Early Detection (Application No. 14/123,722, Patent No. 9,244,074 pending). In addition, as a board-certified pathologist, Dr. Carbone provides diagnostic expertise on mesothelioma to lawyers representing various parties. The remaining authors declare no conflict of interest. Funding Information: This work has in part been supported by the Intramural Program of the National Institutes of Health. We than PhD students Emyr Bakker and Alice Guazzelli, and Erina He from the Medical Arts Department, National Institutes of Health, for helping to create Table 1 and Figure 1 . Publisher Copyright: {\textcopyright} 2018 Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2018",
month = sep,
doi = "10.1016/j.jtho.2018.06.011",
language = "English (US)",
volume = "13",
pages = "1269--1283",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "9",
}